GENETIC-POLYMORPHISM OF CYTOCHROME-P450 CYP2D6 IN ZIMBABWEAN POPULATION

被引:56
作者
MASIMIREMBWA, CM
JOHANSSON, I
HASLER, JA
INGELMANSUNDBERG, M
机构
[1] KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN
[2] UNIV ZIMBABWE,DEPT BIOCHEM,HARARE,ZIMBABWE
来源
PHARMACOGENETICS | 1993年 / 3卷 / 06期
关键词
D O I
10.1097/00008571-199312000-00001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The objective of this study was to determine the CYP2D6 genotype of a black Zimbabwean population. Genotyping was carried out using Eco RI and Xba I RFLP, and allele-specific PCR amplification. Of 114 Zimbabwean samples analysed, no individual homozygous for any of the defect allelic forms CYP2D 6A, CYP2D 6B or CYP2D 6D or combinations thereof was found. The allele frequencies of the three defect genes were 0, 1.8 and 3.9%, respectively. No subject carrying the Xba I 44 kb haplotype, indicative for poor metabolizers among Caucasians, was identified, whereas five individuals being heterozygous with a 29/42 kb haplotype were seen. Three out of the four CYP2D6B alleles found were associated with the 29/42 kb haplotype. Our findings are in agreement with the 0-2% prevalence of poor metabolizers (PMs) in the black populations previously phenotyped. The very low frequency of the CYP2D6B allele in the Zimbabwean population is different from very recent data from black Americans (allele frequency = 8.5%) and might indicate the Caucasian ancestry of this allele. Taken together, our data indicate important interethnic differences in the CYP2D locus between Caucasian, Asian and different black populations.
引用
收藏
页码:275 / 280
页数:6
相关论文
共 27 条
[1]   MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
ABERGWISTEDT, A ;
HUMBLE, M ;
JOHANSSON, I ;
LUNDQVIST, E ;
INGELMANSUNDBERG, M .
LANCET, 1993, 341 (8836) :63-63
[2]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[3]   DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].
BROLY, F ;
GAEDIGK, A ;
HEIM, M ;
EICHELBAUM, M ;
MORIKE, K ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558
[4]   ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION [J].
DAHL, ML ;
JOHANSSON, I ;
PALMERTZ, MP ;
INGELMANSUNDBERG, M ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :12-17
[5]   INTER-ETHNIC DIFFERENCE IN SPARTEINE OXIDATION AMONG GHANAIANS AND GERMANS [J].
EICHELBAUM, M ;
WOOLHOUSE, NM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (01) :79-83
[6]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[7]   GENETIC-BASIS FOR A LOWER PREVALENCE OF DEFICIENT CYP2D6 OXIDATIVE DRUG-METABOLISM PHENOTYPES IN BLACK-AMERICANS [J].
EVANS, WE ;
RELLING, MV ;
RAHMAN, A ;
MCLEOD, HL ;
SCOTT, EP ;
LIN, JS .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (05) :2150-2154
[8]  
GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243
[9]  
GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97
[10]   GENOTYPING OF POOR METABOLIZERS OF DEBRISOQUINE BY ALLELE-SPECIFIC PCR AMPLIFICATION [J].
HEIM, M ;
MEYER, UA .
LANCET, 1990, 336 (8714) :529-532